Stockreport

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma, Inc.  (NVCT) 
PDF Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian [Read more]